Day: August 27, 2025

TORONTO, Aug. 27, 2025 (GLOBE NEWSWIRE) — New Horizon Aircraft (NASDAQ: HOVR), doing business as Horizon Aircraft (“Horizon” or the “Company”), an advanced aerospace engineering company and developer of one of the world’s first hybrid electric Vertical Take-Off and Landing (VTOL) aircraft, today announced that its management team will participate in the following conferences in September: Event: Gabelli Aerospace & Defense SymposiumDate: September 4, 2025Location: New York City – The Harvard ClubLink: https://gabelli.com/event/31st-annual-aerospace-defense-symposium/Management will participate in a fireside chat at 7:45am ET and 1×1 investor meetings. Investors should register at the above link for access to the live fireside chat webcast. Event: Deutsche Bank Aviation Forum: Airlines, Lessors, ManufacturersDate: September...

Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) —  MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its option—granted under the companies’ 2018 license and collaboration agreement—to develop a second dry powder inhalation therapy. The original agreement, which led to U.S. FDA approval of Tyvaso DPI in May 2022, included an option for United Therapeutics to expand the license to include additional active ingredients. Under the terms of the expanded agreement, MannKind will formulate a second investigational molecule using its proprietary Technosphere® platform, and United Therapeutics will conduct preclinical and clinical development. “Building...

Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Patients FLORHAM PARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for oral presentation followed by a 55-minute panel discussion with other experts in this area at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer taking place September 25-28 in Boston, Massachusetts. The oral presentation will highlight interim data from the Phase 1b dose and regimen optimization study of iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade...

US Food and Drug Administration (FDA) has granted Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression. NRx Pharmaceuticals is making NRX-100 available on an expanded access basis upon physician request for patients with serious or life-threatening suicidal depression despite treatment with currently available therapy. Approximately 13 million adults seriously consider suicide each year, according to the CDC. An American dies from suicide every 11 minutes. Physicians may apply for expanded access on behalf of patients who meet expanded access criteria by writing to expandedaccess@nrxpharma.com. Further information may be viewed at https://www.nrxpharma.com/expandedaccess/nrx-100.WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — NRx Pharmaceuticals,...

GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:Wells Fargo 20th Annual Healthcare ConferenceSeptember 4, 20253:00 pm ETWebcast link hereOne-on-one meetingsHCW 27th Annual Global Investment ConferenceSeptember 9, 20251:30 PM ETWebcast link hereOne-on-one meetingsPlease contact your conference representative to request one-on-one meetings. Participants can view the presentations and replays by visiting the Investors page of Emergent’s website. About Emergent BioSolutionsAt Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions...